You can buy or sell MediWound and other stocks, options, ETFs, and crypto commission-free!
MediWound Ltd. Ordinary Shares, also called MediWound, is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of novel products to address needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders. Read More Its medicinal product, NexoBrid, is used to remove eschar in adults patients with deep partial- and full-thickness thermal burns. The company was founded by Lior Rosenberg and Marian Gorecki on January 27, 2000 and is headquartered in Yavne, Israel.
52 Week High
52 Week Low
MediWound (MDWD) CEO Change, Fact Pattern Suggests a Deal May Be Near - SunTrust
(Updated - March 12, 2019 11:06 AM EDT) (updated to expand on analyst comments) SunTrust Robinson Humphrey analyst Bruce Nudell said the CEO change at MediWound (NASDAQ: MDWD), announced this morning, and other facts, could suggest a deal is near. Nudell said, after speaking with management, the move by Gal Cohen to step down after 12 years as CEO was a personal decision to pursue new opportunities. Current Chairman, Stephen Wills, will serve as Active Chairman and will continue to head the ongoing strat...
Seeking AlphaMar 12
MediWound announces leadership changes
MediWound's (NASDAQ:MDWD) CEO, Gal Cohen, has decided to step down from his position. He will end his term by the end of May. Sharon Malka, CFO and COO, will be appointed as CEO, and Stephen T. Wills, Chairman of the Board of Directors, will serve as Active Chairman. Prior to joining MediWound, Mr. Malka held various senior finance roles, including, as a co-founder and partner at Variance Economic Consulting, a full-service financial consulting firm, and as a senior manager at the Israeli member firm of P...
Yahoo FinanceMar 11
Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline
Wall Street expects a year-over-year decline in earnings on higher revenues when MediWound (MDWD) reports results for the quarter ended December 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
-$0.15 per share
Available Mar 25, Pre-Market